Capstan Therapeutics
San Diego
About Capstan Therapeutics
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases using its proprietary CellSeeker tLNP platform. Its technology deploys targeted lipid nanoparticles conjugated with protein binders’such as antibodies’to reprogram specific cell types within the body, including CAR-T cells, without ex vivo manipulation. The lead candidate, CPTX2309, delivers an anti-CD19 CAR payload to CD8Γü║ T cells and aims to reset B cell–driven autoimmune disease, currently in Phase 1 trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $340.0M
- Funding stage: M&A
- Last round: Series B (Mar 2024)
- Website: capstantx.com
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/capstan-therapeutics-18529 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.